- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 30.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 19.06. | VITA LIFE SCIENCES LIMITED: Cleasing Statement | - | ASX | ||
| 19.06. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | - | ASX | ||
| 12.06. | VITA LIFE SCIENCES LIMITED: Guidance | - | ASX | ||
| 12.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 10.06. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 09.06. | VITA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VLS | - | ASX | ||
| 09.06. | VITA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VLS | - | ASX | ||
| 05.06. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 01.06. | VITA LIFE SCIENCES LIMITED: On Market Share Buy Back | - | ASX | ||
| 01.06. | VITA LIFE SCIENCES LIMITED: Notification of buy-back - VLS | - | ASX | ||
| 29.05. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 28.05. | VITA LIFE SCIENCES LIMITED: Results of Meeting | - | ASX | ||
| 28.05. | VITA LIFE SCIENCES LIMITED: AGM Address and Presentation | - | ASX | ||
| 21.05. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 21.05. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 19.05. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 18.05. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,060 | -1,62 % | Green Thumb Industries Inc: Green Thumb to open dispensary in Pennsylvania | ||
| NEKTAR THERAPEUTICS | 61,02 | -1,52 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| ALNYLAM PHARMACEUTICALS | 177,30 | -0,53 % | Alnylam Falls 29% After Reporting Q2 Results | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) plunged after lowering its full-year TTR revenue guidance, overshadowing strong second-quarter revenue growth and a return to profitability.... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,865 | 0,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ADASTRA | 0,115 | 0,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 8,660 | -0,23 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| ACADIA PHARMACEUTICALS | 22,800 | +1,56 % | Acadia Pharmaceuticals Inc.: DAYBU (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen | - Die Entscheidung der Europäischen Kommission wird in den kommenden Monaten erwartet. - Im Falle einer Zulassung wird DAYBU die erste Behandlung von neurobehavioralen Symptomen des Rett-Syndroms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,280 | +1,86 % | Opus Genetics stock coverage initiated at TD Cowen on gene therapy | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 69,00 | -2,82 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| SOLIGENIX | 0,379 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,300 | 0,00 % | ZELIRA THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | ||
| SAVARA | 4,748 | +0,36 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,260 | -4,55 % | Biodexa Pharmaceuticals PLC: Result of General Meeting | July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.